<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03606330</url>
  </required_header>
  <id_info>
    <org_study_id>CM0118-PLI-3</org_study_id>
    <nct_id>NCT03606330</nct_id>
  </id_info>
  <brief_title>Systemic, Pancoronary and Local Coronary Vulnerability</brief_title>
  <acronym>VIP</acronym>
  <official_title>Systemic, Pancoronary and Local Plaque Vulnerability for Image-based Prediction of Acute Coronary Syndromes - the VIP Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cardio Med Medical Center</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Targu Mures, Romania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital of Targu Mures, Romania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Cardio Med Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      • The aim of the VIP study is to investigate the impact of vulnerability markers&#xD;
      (inflammatory serum biomarkers for systemic vulnerability, coronary shear stress and&#xD;
      vulnerability mapping for pancoronary vulnerability, and imaging-based plaque features for&#xD;
      systemic vulnerability) on the rate of major adverse cardiovascular events caused by&#xD;
      progression of the non-culprit lesion in patients with acute ST or non-ST segment elevation&#xD;
      myocardial infarction who undergo revascularization of the culprit lesion during the acute&#xD;
      event. Furthermore, the study will evaluate the rate of progression of non-culprit lesions&#xD;
      towards a higher degree of vulnerability, based on coronary computed tomography angiographic&#xD;
      assessment at 1 year after enrollment.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The project is a prospective, cohort, mono-centric study which will be carried out in the&#xD;
      Center of Advanced Research in Multimodal Cardiac Imaging Cardiomed.&#xD;
&#xD;
      The project will include 100 subjects who present ST and non-ST segment elevation myocardial&#xD;
      infarction at 30 days prior to study enrollment, who underwent emergency revascularization of&#xD;
      the culprit lesion. Samples for systemic serum biomarkers for myocardial injury, myocardial&#xD;
      strain and enhanced systemic inflammation will be collected at the moment of the acute event.&#xD;
      All patients will undergo coronary CT angiography, cardiac perfusion CT and intracoronary&#xD;
      imaging procedures (Intravascular ultrasound - IVUS; Optical Coherence Tomography - OCT) at&#xD;
      the moment of enrollment in the study, for complex assessment of non-culprit coronary&#xD;
      lesions. The endothelial coronary shear stress will be calculated with imaging&#xD;
      post-processing techniques on the CT data acquired at baseline, by using computational fluid&#xD;
      dynamics.&#xD;
&#xD;
      The study will be conducted over a period of 3 years, in which patients will be examined at&#xD;
      baseline, and during several follow-up visits. At the one-year follow-up, the study subjects&#xD;
      will undergo CT coronary angiography for re-evaluation of the non-culprit lesions, in the&#xD;
      prospects of analyzing the rate of plaque progression towards a higher degree of&#xD;
      vulnerability. At the end of the 3-year period, patients will be assessed about the&#xD;
      occurrence of major adverse cardiovascular events and the rate or revascularization for&#xD;
      non-culprit lesions.&#xD;
&#xD;
      Study objectives:&#xD;
&#xD;
      Primary: to investigate the association between systemic, pancoronary and local vulnerability&#xD;
      features of coronary plaques and the risk for major adverse cardiac events - MACE (all-cause&#xD;
      mortality, cardiovascular death, myocardial infarction, repeated revascularization, repeated&#xD;
      hospitalizations for cardiovascular related incidents, cerebrovascular events) during a&#xD;
      3-year follow-up.&#xD;
&#xD;
      Secondary: to assess the rate of progression for the non-culprit lesions towards a higher&#xD;
      degree of vulnerability, as evaluated via coronary CT angiography at 1 year after enrollment,&#xD;
      in relation to systemic, pancoronary and local vulnerability features at baseline.&#xD;
&#xD;
      To identify the type of vulnerability (systemic, pancoronary or local) with the highest&#xD;
      impact on plaque progression and future MACE&#xD;
&#xD;
      Study Timeline:&#xD;
&#xD;
      Baseline (day 0)&#xD;
&#xD;
        -  Obtain and document consent from participant on study consent form.&#xD;
&#xD;
        -  Verify inclusion/exclusion criteria.&#xD;
&#xD;
        -  Obtain demographic information, medical history, medication history, alcohol and tobacco&#xD;
           use history.&#xD;
&#xD;
        -  Record results of physical examinations and 12-lead ECG.&#xD;
&#xD;
        -  Collect blood specimens.&#xD;
&#xD;
        -  Imaging procedures: transthoracic 2-D echocardiography, 128-multisclice CT angiography,&#xD;
           cardiac perfusion CT, IVUS, OCT&#xD;
&#xD;
      Visit 1 (month 1)&#xD;
&#xD;
        -  Record results of physical examinations, 12-lead ECG and medical history.&#xD;
&#xD;
        -  Imaging procedures: transthoracic 2-D echocardiography&#xD;
&#xD;
      Visit 2 (month 3)&#xD;
&#xD;
      • Telephone follow-up&#xD;
&#xD;
      Visit 3 (month 6)&#xD;
&#xD;
        -  Record results of physical examinations, 12-lead ECG and medical history.&#xD;
&#xD;
        -  Imaging procedures: transthoracic 2-D echocardiography&#xD;
&#xD;
      Visit 4 (month 12)&#xD;
&#xD;
        -  Record results of physical examinations, 12-lead ECG and medical history.&#xD;
&#xD;
        -  Imaging procedures: transthoracic 2-D echocardiography, 128-multislice CT coronary&#xD;
           angiography for evaluation of non-culprit lesion&#xD;
&#xD;
        -  End-point evaluation&#xD;
&#xD;
      Visit 5 (month 15)&#xD;
&#xD;
      • Telephone follow-up&#xD;
&#xD;
      Visit 6 (month 18)&#xD;
&#xD;
      • Telephone follow-up&#xD;
&#xD;
      Visit 7 (month 24)&#xD;
&#xD;
        -  Record results of physical examinations, 12-lead ECG and medical history.&#xD;
&#xD;
        -  Imaging procedures: transthoracic 2-D echocardiography.&#xD;
&#xD;
        -  End-point evaluation&#xD;
&#xD;
      Visit 8 (month 30)&#xD;
&#xD;
      • Telephone follow-up&#xD;
&#xD;
      Final study visit (month 36)&#xD;
&#xD;
        -  Record results of physical examinations, 12-lead ECG and medical history.&#xD;
&#xD;
        -  Imaging procedures: transthoracic 2-D echocardiography&#xD;
&#xD;
        -  End-point evaluation.&#xD;
&#xD;
      Study procedures:&#xD;
&#xD;
        -  Clinical examination, medical history&#xD;
&#xD;
        -  12-lead ECG&#xD;
&#xD;
        -  2D transthoracic echocardiography with measurement of: cardiac diameters, volumes,&#xD;
           valvular function and regurgitation, pressure gradients, pericardial fat thickness,&#xD;
           pericardial effusion, left ventricular global and regional function and ejection&#xD;
           fraction.&#xD;
&#xD;
        -  128-multislice CT coronary angiography with the evaluation of: epicardial fat volume,&#xD;
           plaque burden, total and local calcium score, markers for lesion severity (degree of&#xD;
           stenosis, lesion length, lumen area and diameter, minimum and maximum plaque thickness);&#xD;
           morphological plaque characteristics (plaque related volumes, plaque burden, vascular&#xD;
           indexes - remodeling and eccentricity index); plaque components evaluated via volumetric&#xD;
           and planimetric units (necrotic core, fibrofatty tissue, fibrotic tissue, dense&#xD;
           calcium); markers of plaque vulnerability (necrotic core, low attenuation plaque, spotty&#xD;
           calcification, napkin ring sign, positive remodeling).&#xD;
&#xD;
        -  Shear stress evaluation of CT acquired images and computational fluid dynamics&#xD;
&#xD;
        -  Intracoronary imaging techniques: IVUS and OCT with evaluation of plaque&#xD;
           characteristics.&#xD;
&#xD;
        -  Venous blood sample collection during the acute coronary event for evaluation of serum&#xD;
           levels of hsCRP, IL-6, matrixmetalloproteases MMP9, Adhesion molecules (VCAM, ICAM),&#xD;
           alfa tumour necrosis factor, hs-cTnI, NTproBNP&#xD;
&#xD;
      Data collection: In a dedicated database that includes all patient information, demographics,&#xD;
      medical history, medication, therapeutic procedures, information derived from imaging&#xD;
      techniques (echocardiography, CT angiography, CT imaging post-processing and shear stress&#xD;
      evaluation).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 22, 2018</start_date>
  <completion_date type="Anticipated">November 1, 2022</completion_date>
  <primary_completion_date type="Actual">October 22, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>MACE rate - Major adverse cardiovascular events</measure>
    <time_frame>36 months</time_frame>
    <description>Acute coronary syndromes (unstable angina, ST and non-ST elevation myocardial infarction), emergency revascularization of non-culprit lesions, repeated hospitalizations for cardiovascular reasons, acute cerebrovascular event.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Severity progression of non-culprit coronary lesions</measure>
    <time_frame>12 months</time_frame>
    <description>Reevaluation of the non-culprit lesions via 128-multislice CT coronary angiography with analysis of the degree of stenosis caused by the non-culprit lesion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression rate of CT markers for coronary plaque vulnerability</measure>
    <time_frame>12 months</time_frame>
    <description>Reevaluation of the non-culprit lesions via 128-multislice CT coronary angiography with analysis of the number of CT markers for coronary plaque vulnerability (low attenuation plaque, spotty calcification, napkin ring sign, positive remodeling).</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Coronary Stenosis</condition>
  <condition>Acute Coronary Syndrome</condition>
  <condition>Acute Myocardial Infarction</condition>
  <condition>Atheromatous Plaques</condition>
  <condition>Atheroscleroses, Coronary</condition>
  <condition>Non-ST Elevation Myocardial Infarction (nSTEMI)</condition>
  <arm_group>
    <arm_group_label>VP-SG 01</arm_group_label>
    <description>Study subjects that present MACE at the 36 months follow-up</description>
  </arm_group>
  <arm_group>
    <arm_group_label>VP-SG 02</arm_group_label>
    <description>Study subjects that do not present MACE at the 36 months follow-up</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Cardiac imaging tests</intervention_name>
    <description>2D transthoracic echocardiography&#xD;
128-multislice CT coronary angiography with the evaluation of: epicardial fat volume, plaque burden, total and local calcium score, markers for lesion severity; morphological plaque characteristics; plaque components evaluated via volumetric and planimetric units; markers of plaque vulnerability (necrotic core, low attenuation plaque, spotty calcification, napkin ring sign, positive remodeling).&#xD;
Shear stress evaluation via computational fluid dynamics.&#xD;
Intracoronary imaging techniques: IVUS and OCT.</description>
    <arm_group_label>VP-SG 01</arm_group_label>
    <arm_group_label>VP-SG 02</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Venous blood sample collection</intervention_name>
    <description>Venous blood sample collection during the acute coronary event for evaluation of serum levels of hsCRP, IL-6, matrixmetalloproteases MMP9, Adhesion molecules (VCAM, ICAM), alfa tumour necrosis factor, hs-cTnI, NTproBNP</description>
    <arm_group_label>VP-SG 01</arm_group_label>
    <arm_group_label>VP-SG 02</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Venous blood sample collection during the acute coronary event for evaluation of serum levels&#xD;
      of hsCRP, IL-6, matrixmetalloproteases MMP9, Adhesion molecules (VCAM, ICAM), alfa tumour&#xD;
      necrosis factor, hs-cTnI, NTproBNP&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        100 patients with present ST and non-ST segment elevation myocardial infarction at 30 days&#xD;
        prior to study enrollment, who underwent emergency revascularization of the culprit lesion.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients aged over 18 years old that have signed the written informed consent;&#xD;
&#xD;
          -  Patients with ST and non-ST segment elevation myocardial infarction (as stated in the&#xD;
             Third Universal Definition of Myocardial Infarction) at 30 days prior to&#xD;
             randomization;&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  unwillingness or incapacity to provide informed consent (and if consent of legal&#xD;
             guardian or family is not available);&#xD;
&#xD;
          -  acute myocardial infarction at the moment of randomization (as these patients are&#xD;
             referred to the hospital for emergency invasive coronary angiography and&#xD;
             revascularization)&#xD;
&#xD;
          -  conditions that present an estimated life expectancy of under 5 years;&#xD;
&#xD;
          -  acute renal failure or terminal stage chronic kidney disease;&#xD;
&#xD;
          -  pregnancy or lactation and women of reproductive age who are not using any&#xD;
             contraceptive method;&#xD;
&#xD;
          -  allergy and history of allergic reactions to iodine contrast media;&#xD;
&#xD;
          -  active malignancy or malignancy within the last 1 year prior to enrollment;&#xD;
&#xD;
          -  patients who, in the opinion of the investigators are not compliant and will not&#xD;
             present for study visits.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Theodora Benedek, Professor</last_name>
    <role>Study Director</role>
    <affiliation>Cardio Med Medical Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Theodora Benedek, Professor</last_name>
    <phone>+40 265 217 333</phone>
    <email>theodora.benedek@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Diana Opincariu, MD</last_name>
    <phone>+40 265 217 333</phone>
    <email>diana.opincariu@yahoo.ro</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cardio Med</name>
      <address>
        <city>Târgu-Mureş</city>
        <state>Mures</state>
        <country>Romania</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Theodora Benedek, Prof</last_name>
      <phone>+40722560549</phone>
      <email>theodora.benedek@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Imre Benedek, Prof</last_name>
      <phone>+40265211595</phone>
      <email>imrebenedek@yahoo.com</email>
    </contact_backup>
    <investigator>
      <last_name>Diana Opincariu, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nora Rat, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Monica Chitu, M.D., PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Romania</country>
  </location_countries>
  <verification_date>December 2019</verification_date>
  <study_first_submitted>June 26, 2018</study_first_submitted>
  <study_first_submitted_qc>July 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 30, 2018</study_first_posted>
  <last_update_submitted>December 11, 2019</last_update_submitted>
  <last_update_submitted_qc>December 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>coronary artery disease</keyword>
  <keyword>myocardial infarction</keyword>
  <keyword>cardiac imaging techniques</keyword>
  <keyword>major adverse cardiovascular events</keyword>
  <keyword>vulnerable coronary plaques</keyword>
  <keyword>serum biomarkers</keyword>
  <keyword>coronary shear stress</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Atherosclerosis</mesh_term>
    <mesh_term>Coronary Stenosis</mesh_term>
    <mesh_term>Non-ST Elevated Myocardial Infarction</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Plaque, Atherosclerotic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All IPD that underlie results in a publication will be available for interested parties.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>The IPD sharing frame is starting 6 months after publication.</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

